Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Treatment of Lupus Nephritis with Cyclosporine – An Outcome Analysis

Rihova Z.a · Vankova Z.a · Maixnerova D.a · Dostal C.b · Jancova E.a · Honsova E.c · Merta M.a · Rysava R.a · Tesař V.a

Author affiliations

aNephrology Unit and bInstitute for Rheumatology, 1st Medical Faculty, Charles University, and cPathology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Related Articles for ""

Kidney Blood Press Res 2007;30:124–128

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: February 13, 2006
Accepted: March 05, 2007
Published online: March 30, 2007
Issue release date: April 2007

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 4

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: https://www.karger.com/KBR

Abstract

Background: The optimal therapy for lupus nephritis (LN), including the role of cyclosporine (CsA), still lacks scientifically valid clinical experience. We evaluated the efficacy of CsA in the induction and maintenance treatment of patients with biopsy-proven LN. Patients and Methods: A total of 31 patients (25 women, 6 men, mean age 29.5 years) were enrolled in the study. The majority had proliferative LN. The mean follow-up was 85.6 ± 24.7 months. Results: CsA was used as first-line treatment in 38.7% of patients and as second-line treatment in 61.3% of patients. Complete remission was achieved in 93.5% of patients. The relapse rate was 45.2%. The mean disease-free interval was 33 months. At the end of follow-up, a total of 67.9% of the patients were in remission. The treatment led to significant improvement in proteinuria (p = 0.001) and stabilization of renal function. Conclusion: CsA might be an appropriate and a less toxic alternative drug for LN both as a first-choice and rescue therapy.

© 2007 S. Karger AG, Basel


References

  1. Rothfield N: Clinical features of SLE; in Kelley WN et al (eds): Textbook of Rheumatology. Philadelphia, Saunders, 1981.
  2. Dooley MA, Falk RJ: Immunosuppressive therapy of lupus nephritis. Lupus 1998;7:630–634.
  3. Radharkrishnan J, Kunis CL, D’Agati VD, et al: Cyclosporin treatment of lupus membranous nephropathy. Clin Nephrol 1994;42:147–154.
    External Resources
  4. Hallegua D, Wallace DJ, Metzger AL, et al: Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 2000;9:241–251.
  5. Yin PD, Yang XY: A clinical study on low dose cyclosporin A in the treatment of lupus nephritis. Zhonghua Nei Ke Za Zhi 1994;33:684–686.
  6. Favre H, Miescher PA, Huang YP, et al: Cyclosporin in the treatment of lupus nephritis. Am J Nephrol 1989;9:57–60.
  7. Dostal C, Tesar V, Rychlik I, et al: Effect of one year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 1998;7:29–36.
  8. Tam LS, Li EK, Leung CB, et al: Long-term treatment of lupus nephritis with cyclosporin A. QJM 1998;91:573–580.
  9. Dostal C, Tesar V, Rysava R, et al: Cyclofa-lune (2002) lupus nephritis-randomized controlled multicentric therapeutic comparation with cyclosporin A versus cyclophosphamide: running evaluation. Ann Rheum Dis 2004;63(suppl 1):223.
  10. Bombardieri C et al and Comittee on Prognostic Studies in SLE: Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992;35:630–640.
  11. Cattran DC: Cyclosporine in the treatment of idiopathic focal segmental glomerulosclerosis. Semin Nephrol 2003;23:234–241.
  12. Cattran DC: Mycophenolate mofetil and cyclosporine therapy in membranous nephropathy. Semin Nephrol 2003;23:272–277.
  13. Feutren G, Querin S, Noel LH, et al: Effects of cyclosporin in severe lupus erythematosus. J Pediatr 1987;111:1063–1068.
  14. Contreras G, Pardo V, Leclercq B, et al: Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971–980.
  15. Lenz O, Contreras G: Treatment options for severe lupus nephritis. Arch Immunol Ther Exp 2004;52:356–365.
  16. Bogdanovic R, Nikolic V, Pasic S: Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol 2004;19:36–44.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: February 13, 2006
Accepted: March 05, 2007
Published online: March 30, 2007
Issue release date: April 2007

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 4

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: https://www.karger.com/KBR


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.